Get startedLog in
    Picture of Sichuan Kelun-Biotech Biopharmaceutical logo

    6990 — Sichuan Kelun-Biotech Biopharmaceutical News Story

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareSpeculativeLarge CapHigh Flyer
    All News

    Brief: Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (Sac-TMT) Approved For Marketing In Second Indication By NMPA For EGFRm NSCLC

    Picture of Sichuan Kelun-Biotech Biopharmaceutical logoSichuan Kelun-Biotech Biopharmaceutical
    10/03/2025 10:45
    March 10 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:

KELUN-BIOTECH'S TROP2 ADC SACITUZUMAB TIRUMOTECAN (SAC-TMT) APPROVED FOR MARKETING IN SECOND INDICATION BY NMPA FOR EGFRM NSCLC

Source text: ID:nPn76DkP5a

Further company coverage: 6990.HK

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Sichuan Kelun-Biotech Biopharmaceutical

    See all news